[PDF] Top 20 Evaluación y Plan de Mejora de las Condiciones de Seguridad e Higiene en un Taller de Mecanizados
Has 10000 "Evaluación y Plan de Mejora de las Condiciones de Seguridad e Higiene en un Taller de Mecanizados" found on our website. Below are the top 20 most common "Evaluación y Plan de Mejora de las Condiciones de Seguridad e Higiene en un Taller de Mecanizados".
Copolymer micelles function as pH-responsive nanocarriers to enhance the cytotoxicity of a HER2 aptamer in HER2-positive breast cancer cells
... target cells is crucial for nucleic acid-based ...using pH-responsive PEG 8 -PDPA 100 -PEG 8 polymer micelles as ...these pH-responsive micelle-like nanoparticles (MNPs) to ... See full document
7
Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2 positive Breast Cancer Cells in Vitro
... first aptamer drug, Mucagen, was approved for clinical use years ...Other aptamer-based agents are being actively tested in clinical trials ...significantly enhance the treatment outcome in animal ... See full document
14
<p>A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells</p>
... stimuli- responsive nanovalves 7 such as inorganic nanoparticles, 8 polymers, 9–11 biomacromolecules 12-14 and supramolecular assemblies 15,16 to enable controlled drug release in response to external or internal ... See full document
9
HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo
... PCDH HER2 and 231 PCDH HER2 cells displayed slightly lower Fak protein expression levels but markedly higher phosphorylated Fak (pFak, including Y397, Y576, and Y925) levels; SK-BR-3 HER2i ... See full document
109
Polymer–lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells
... cytometry. Breast cancer cells were incubated with free CFPE, CFPE-Sali-NP, or CFPE-Sali-NP- her2 for 4 ...the cells for 30 min prior to treatment with ...hPlc. Breast ... See full document
6
A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti HER2 drug resistant cell lines
... phosphatase) function markers, and hema- tological parameters (% neutrophils, % lymphocytes, % monocytes, % platelets, hemoglobine and % hematocrit) were determined in serum of control and G28UCM- treated ... See full document
7
Modulation of expression of heat shock proteins and apoptosis by Flueggea leucopyrus (Willd) decoction in three breast cancer phenotypes
... h) cells were har- vested and used for total RNA extraction for reverse tran- scription PCR (RT- ...cultured cells, using TRIzol reagent according to the method described by Samarakoon et ...treated ... See full document
71
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
... mononuclear cells (PBMCs) of healthy donors were used as effector cells to deter- mine the in vitro efficacy of the ...These cells were isolated from blood samples by Ficoll-Hypaque (Sigma) density ... See full document
9
Appendicitis caused by the metastasis of HER2-positive breast cancer
... ILC of the breast accounts for 14 % of all breast cancer cases [2] and presents with a loss of E-cadherin expression [3]. It can metastasize to the abdominal cavity as peritoneal dissemination, ... See full document
24
Role of pertuzumab in the treatment of HER2-positive breast cancer
... were not overexpressing the HER2 receptor. In this evalu- ation, pertuzumab was well tolerated at all dose levels, and a maximum tolerated dose was not reached. Toxicity was generally mild as twelve grade 3/4 ... See full document
20
PYK2 promotes HER2-positive breast cancer invasion
... that HER2+/ER−/PR- cancer cells were the most resistant to ...ductal breast cancer, and this correlated with increased expression of HER2 ...in HER2+/ER−/PR- cancer ... See full document
6
New developments in the treatment of HER2-positive breast cancer
... metastatic breast cancers show increased expression of the human epidermal growth factor receptor-2 (HER2) tyrosine ...Two HER2-specific therapies are currently approved for clinical treatment of ... See full document
21
A Novel Immunohistochemical Signature with the Quantification of HER2 Predicts the Complete Response in HER2-Positive Breast Cancer
... Standardized surgery was performed after approximately 6 weeks of neoadjuvant chemotherapy (NTC). The adjuvant radiotherapy (AR) was administered in the patients subjected to conservative surgery in both breast ... See full document
5
Occurrence of breast cancer subtypes in adolescent and young adult women
... of breast cancer subtypes by age group (15 to 39 years versus 40 to 49 years; 15 to 39 years versus older than 50 years), and we used logistic regression to calculate odds ratios (OR) and associated 95% ... See full document
9
Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer
... of breast cancer, especially in patients with HER2 overexpression ...wild-type HER2 overexpression occurs in 20–30% of breast cancers, Bose et ...of breast cancer patients ... See full document
204
HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients
... + HER2 level were further tested by fluorescence in situ ...+ HER2 level by IHC and/or HER2/neu gene amplification by fluorescence in situ hybridization were described as being ...The ... See full document
10
Current neoadjuvant treatment options for HER2 positive breast cancer
... with breast cancer demonstrate amplification of the human epidermal receptor type 2 (HER2) gene, the expression of which is associated with a relatively poor prognosis independent of other clinical ... See full document
65
The expanding role of pertuzumab in the treatment of HER2-positive breast cancer
... with HER2-positive, locally advanced (T2-3, N2-3, M0; T4a–c, any N, M0), inflammatory (T4d, any N, M0), or early-stage breast cancer (tumors greater than 2 cm in diameter) were enrolled and ... See full document
14
Optimizing Treatments for ER/PR Positive HER2/neu Negative Metastatic Breast Cancer: US Oncologist Survey
... ER/PR Positive HER2neu Negative Metastatic Breast ...of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact ... See full document
5
Original Article Outcome prediction values of soluble human epidermal growth factor receptor-2 extracellular domain in metastatic breast cancer
... of breast can- cer and persistent efforts have been underway to develop more tailored ...of breast cancer patients, it has been proposed as a novel biomarker to monitor treatment response and disease ... See full document
23
Related subjects